SGN-00101 Immunotherapy in Treating Patients With Grade III Cervical Intraepithelial Neoplasia
Completed · Phase 2
Conditions studied: Cervical Cancer, Precancerous Condition
In brief
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer or to treat early cancer. SGN-00101 may be effective in preventing the development of cervical cancer in patients who have cervical intraepithelial neoplasia. PURPOSE: This phase II trial is studying how well SGN-00101 immunotherapy works in preventing cervical cancer in patients with grade III cervical intraepithelial neoplasia.
Key facts
- Study ID
- NCT00075569
- Run by
- Albert Einstein College of Medicine
- People needed
- 64
- Starts
- 2004-03-01
- Expected to finish
- 2005-08-01
- Last updated by the study team
- 2018-05-21
Who can join
Age: 18 and older, up to 120. Sex: female. Healthy volunteers: not accepted.
Where it is running
- New York Weill Cornell Cancer Center at Cornell University — New York, New York, United States
- Albert Einstein Cancer Center at Albert Einstein College of Medicine — The Bronx, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.